Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

Antiepileptic Drugs: Glutamate Antagonists

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...

Antiepileptic Drugs: Calcium Channel Blockers

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...

Epilepsy and Seizures: Overview

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cardiac sympathetic denervation and anxiety in Parkinson disease.

Parkinsonism & related disorders·2024

Same author

Performance evaluation of two multiplex qualitative RT-PCR assays for detection of respiratory infection in paediatric population.

The Malaysian journal of pathology·2023

Same author

The effects of N-acetylcysteine on lung alveolar epithelial cells infected with respiratory syncytial virus.

The Malaysian journal of pathology·2023

Same author

IL-23/IL-17 axis in the pathogenesis and treatment of systemic lupus erythematosus and rheumatoid arthritis.

The Malaysian journal of pathology·2020

Same author

MEK inhibitor resistance mechanisms and recent developments in combination trials.

Cancer treatment reviews·2020

Same author

The end of 'cordon sanitaire' in Wuhan: the role of non-pharmaceutical interventions against COVID-19.

Public health·2020

Search research articles

Related Experiment Video

Updated: Jul 3, 2026

Simultaneous Recording of Electroretinography and Visual Evoked Potentials in Anesthetized Rats

Simultaneous Recording of Electroretinography and Visual Evoked Potentials in Anesthetized Rats

Published on: July 1, 2016

Vigabatrin-induced visual dysfunction in Chinese patients with refractory epilepsy.

A C F Hui¹, D T L Liu, K K Wong

¹Division of Neurology, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong.

European Journal of Ophthalmology

|July 9, 2008

Summary

Vigabatrin, an antiepileptic drug, caused significant visual field defects in 55.6% of Chinese patients. Regular visual field monitoring is recommended to detect early retinal damage in patients using this medication.

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jul 3, 2026

Simultaneous Recording of Electroretinography and Visual Evoked Potentials in Anesthetized Rats

Simultaneous Recording of Electroretinography and Visual Evoked Potentials in Anesthetized Rats

Published on: July 1, 2016

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Area of Science:

Ophthalmology
Neurology
Pharmacology

Background:

Bilateral visual field constriction is a known risk associated with vigabatrin, an antiepileptic drug.
Limited data exist on vigabatrin's retinal toxicity in Asian populations.

Purpose of the Study:

To investigate the ophthalmologic findings in Chinese patients using vigabatrin.
To determine the incidence of visual field defects in this population.

Main Methods:

Ophthalmologic examinations were conducted on Chinese patients with refractory epilepsy, comparing vigabatrin users to a control group on other antiepileptic drugs.
Methods included visual acuity testing, intraocular pressure measurement, slit lamp biomicroscopy, and automated perimetry.

Main Results:

Fifty-five point six percent (55.6%) of vigabatrin users (n=18) exhibited significant bilateral visual field defects, predominantly concentric.
No visual field defects were observed in the control group.
Treatment duration ranged from 13 months to 5 years with a mean daily dosage of 1581 mg.

Conclusions:

A high prevalence of visual field constriction was confirmed in Chinese patients using vigabatrin.
Novel techniques like retinal nerve fiber layer thickness measurement may reveal earlier retinal damage.
Routine visual field monitoring is advised for patients on long-term vigabatrin therapy.